Yu-Lin Chang Selected Research

ONX 0912

1/2019	Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
1/2019	Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yu-Lin Chang Research Topics

Disease

2	Neoplasms (Cancer) 11/2022 - 04/2021
2	Multiple Myeloma 01/2019 - 01/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2023
1	Body Weight (Weight, Body) 05/2023
1	Hemorrhage 08/2021
1	Hemorrhagic Shock 08/2021
1	Stroke (Strokes) 04/2018
1	Neutropenia 05/2013
1	Colorectal Neoplasms (Colorectal Cancer) 05/2013
1	Peripheral Nervous System Diseases (PNS Diseases) 05/2013

Drug/Important Bio-Agent (IBA)

2	ONX 0912IBA 01/2019 - 01/2019
2	Proteasome InhibitorsIBA 01/2019 - 01/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 01/2019
1	IpilimumabIBA 05/2023
1	cabozantinibIBA 05/2023
1	NivolumabIBA 05/2023
1	Soluble Guanylyl CyclaseIBA 08/2021
1	Carbon MonoxideIBA 08/2021
1	Guanosine Monophosphate (5' Guanylic Acid)IBA 08/2021
1	NS 2028IBA 08/2021
1	Biomarkers (Surrogate Marker)IBA 04/2021
1	pomalidomideIBA 01/2019
1	Sorafenib (BAY 43-9006)FDA Link 05/2013
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 05/2013
1	Leucovorin (Folinic Acid)FDA Link 05/2013
1	Fluorouracil (Carac)FDA LinkGeneric 05/2013

Therapy/Procedure

1	Chemoradiotherapy 11/2022
1	Resuscitation 08/2021
1	Activities of Daily Living (ADL) 04/2018